European Primary Care Cardiovascular Society

AHA 2021

EPCCS reports on studies presented at the digital AHA 2021. Find coverage of the latest CV news on IPCCS.org.

An algorithm-based program for cardiovascular healthcare

3' education - Nov. 22, 2021 - Alexander J. Blood, MD
Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.

AHA 2021 Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.

Remote program for improvement of lipid and hypertension management

News - Nov. 22, 2021

AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.

SGLT2i reduces composite of CV death or HF hospitalization in patients with HF and LVEF ≥50%

News - Nov. 17, 2021

AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.

Does low-dose aspirin lower risk of dementia in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage
 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

No significant effect of aspirin on dementia outcomes in patients with T2DM

News - Nov. 16, 2021

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

Assessing the effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD
In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

AHA 2021 In this video, prof. Marcus explains the methodology of n-of-1 trials in the I-STOP-AF trial and summarizes the findings.

Testing individual triggers for AF

News - Nov. 15, 2021

AHA 2021 In the I-STOP AF trial, n-of-1 trials with individual triggers did not result in a change in AF-related quality of life compared to monitoring only.

SGLT2 inhibitor improves symptoms in heart failure

News - Nov. 15, 2021

AHA 2021 The CHIEF-HF study showed that canagliflozin improved symptoms in HF as measured by KCCQ-TSS. The benefits with canagliflozin were observed as early as 2 weeks and sustained until the end of treatment at 3 months.

Highly-purified icosapent ethyl does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

Effects of coffee consumption on acute physiological changes: A randomized trial

3' education - Nov. 14, 2021 - Prof. Gregory Marcus, MD
Prof. Gregory Marcus explains the design and results of the CRAVE trial. The study found no relationship between coffee consumption and PACs. In contrast, random assignment to coffee consumption was associated with an increased risk of PVCs.

AHA 2021 Prof. Gregory Marcus explains the design and results of the CRAVE trial. The study found no relationship between coffee consumption and PACs. In contrast, random assignment to coffee consumption was associated with an increased risk of PVCs.

Use of non-physician providers to control BP: An ambitious project

3' education - Nov. 14, 2021 - Prof. Keith Ferdinand, MD
Prof. Ferdinand summarizes and discusses the results from the Chinese Rural Hypertension Control (CRHC) Project.

AHA 2021 Prof. Ferdinand summarizes and discusses the results from the Chinese Rural Hypertension Control (CRHC) Project.

Screening for AF using a novel software algorithm with input of data of Fitbit wearables

News - Nov. 14, 2021
A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).

AHA 2021 A novel software algorithm with input of irregular heart rhythm detection by Fitbit wearables had a positive predictive value of 98% for undiagnosed atrial fibrillation (AF).

AHA 2021